Salute e Benessere

Virbac : Public release of Virbac Annual Report at 31 December 2023 (ESEF…

Public release of Virbac Annual Report at 31 December 2023 (ESEF format).The Group released and filed its 2023 Annual Report with the French “Autorité des marchés financiers”.The document is also available on the corporate website, at corporate.virbac.com, under “Investors”, “Financial Reports” at the ESEF format and pdf format. Attachment Public release of Virbac Annual Report at 31 December 2023 (ESEF format)

Basilea shareholders approve all proposals of the board of directors at the…

Allschwil, Switzerland, April 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today's annual general meeting (AGM) for the financial year 2023.At the AGM, the shareholders approved the annual report, the financial statements and the consolidated financial statements for...

Casino Group: Reverse share split

Casino launches reverse share splitParis, 24 April 2024Casino, Guichard-Perrachon (" Casino") announces today (i) the implementation of the reverse share split of its share capital through the exchange of one hundred (100) existing shares for one (1) new share and (ii) the reduction in share capital by reducing the nominal value of shares decided by the Board of Directors of Casino on 24 April 2024, in accordance with the twelfth and thirteenth resolutions approved by the…

Casino Group: Q1 2024

FIRST-QUARTER 2024 Consolidated net sales of €2.1bn in Q1 2024 1 Convenience brands: €1.8bn (+0.1% on a same-store basis)Monoprix: €1.1bn (+0.7%)Franprix: €406m (+0.6%)Casino: €349m (-2.4%) Cdiscount:€242m (-21.1%) linked to the planned reduction in direct sales Adjusted EBITDA after lease payments 2of -€10m(vs. €35m in Q1 2023) Free cash flow excluding disposal plan/restructuring costs 3of -€327m in Q1 2024(-€226m in Q1 2023) after payment of...

CQ Medical™ (formerly CIVCO Radiotherapy and Qfix) is Exhibiting New Brand and…

The company encourages attendees to visit booth #820 to see how two legacy companies are integrating their market-leading solutions, uniquely combining medical technology with patient empathy, to help achieve better patient outcomes. Two special product unveilings will take place on Friday, 3 May at 19:18, which you will want to attend. The company encourages attendees to visit booth #820 to see how two legacy companies are integrating their market-leading solutions, uniquely combining…

Vaccines Market Worth $94.9 billion | MarketsandMarkets™

Browse in-depth TOC on "Vaccines Market"394 - Tables57 - Figures414 - Pages Browse in-depth TOC on "Vaccines Market" 394 - Tables 57 - Figures 414 - Pages Vaccines Market Scope: The conjugate vaccine segment is expected to have the dominant share of the vaccine market (excluding COVID-19 vaccines) in 2023. Based on technology, the global vaccines market (excluding COVID-19 vaccines) is segmented into recombinant vaccines, conjugate vaccines, live attenuated vaccines,...

Ultimovacs Announces Poster Presentation at the 2024 American Society of…

NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024:Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (NCT04382664), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. INITIUM is an Ultimovacs-sponsored randomized, comparative, multicenter Phase II...

PHARMANUTRA: SUCROSOMIAL® TECHNOLOGY ARRIVES IN UNITED STATES

The Italian company's initial success inthe United States, where it has already obtained numerous patent and scientific recognitions from the medical community over many years, has come as a result of the effectiveness of the proprietary technologies which form the basis of the formulation of the products with which, in just 20 years, it has achieved leadership in the Italian market and significant shares of the foreign markets where it operates through exclusive distributors...

Unity Health Toronto partners with Cure51 to identify the biological…

As the newest addition to Cure51's extensive network of over 50 medical partners globally, Unity Health Toronto brings a wealth of expertise and resources to the project. With a shared commitment to advancing medical innovation and improving patient outcomes, this partnership is poised to drive groundbreaking discoveries in the field of oncology. Cure51 is building the first global clinical and multi omics database of exceptional survivors with over 1100 patients from all continents...

RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge…

LOS ANGELES and AMSTERDAM, April24, 2024(GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing...

Novo Nordisk A/S - Articles of Association, April 2024

Novo Nordisk's Articles of Association, April 2024 Attachment Articles of Association 24 Apr 2024

Novo Nordisk A/S – Reduction of the share capital

Bagsværd, Denmark, 24 April 2024– At Novo Nordisk's Annual General Meeting on 21 March 2024, it was decided to reduce the company's B share capital from DKK 343,512,800 to DKK 339,012,800 by cancellation of part of the company's portfolio of own B shares equal to a nominal value of DKK 4,500,000 divided into 45,000,000 B shares of DKK 0.10 each. Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B...

Lykos Therapeutics Announces Completion of European Phase 2 Study for…

"Given the substantial need for new treatment options for individuals with mental health conditions in Europe, the completion of this Phase 2 study is an important step to helping address unmet needs outside the United States," said Amy Emerson, chief executive officer at Lykos Therapeutics. "By pursuing FDA approval of MDMA-assisted therapy first, we believe the learnings will be beneficial as we determine our regulatory strategy in the United Kingdom and Europe. We are exploring…

Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth…

2023 business growth serving patient needs 2023 business growth serving patient needs Chiesi reached over €3 billion in sales – a 10% growth (+12% @CER) on the previous year – maintaining an EBIDTA of approximately 30% for the fourth consecutive year. In 2023, the Company reinforced its strong momentum across geographies and business areas. At constant exchange rates (@CER), growth was observed in all three of the Group's business areas (AIR - respiratory diseases, RARE - rare and...

Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680…

Vibrance-1 is a phase 2, randomized, double-blind, dose-range-finding, placebo-controlled study evaluating the safety and efficacy of ALKS 2680 in people with NT1. Participants will be randomized to receive one of three doses of ALKS 2680 (4 mg, 6 mg or 8 mg) or placebo to be taken once-daily for six weeks. The primary endpoint will assess whether participants taking ALKS 2680 experience a greater decrease in sleepiness compared to participants taking placebo alone, as measured by the change in…

Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License…

Program is the Product of a Research Collaboration between Biolojic Design and Nektar entered in 2021 The antibody program selected for development (now known as NKTR-0165) is designed to modulate the TNFR2 pathway in order to agonize - or activate - T regulatory cells and other anti-inflammatory cell populations, making this a promising approach to stimulating the immune system in ulcerative colitis, multiple sclerosis, vitiligo, and other autoimmune disease states. Under the 2021...

Pharma Parenteral Packaging Market in the North America is Anticipated to…

Get Free Sample Report Pages: https://www.insightaceanalytic.com/request-sample/2446 Get Free Sample Report Pages: https://www.insightaceanalytic.com/request-sample/2446 Pharma parenteral packaging is created to hold and transport sterile pharmaceutical goods administered through injections. These packaging techniques keep medical products safe, contamination-free, and undamaged in storage, and transit and maintain their potency. The growing pharmaceutical sector, increasing...

Esaote Group: Shareholders' Meeting approves financial statements as of 31…

All the main Group consolidated figures for the 2023 financial year are up: net sales revenues at€ 273.2 million( +6.5%on 2022);EBITDA at€ 41.7 million( +24.5%on 2022) ; Group operating income at€ 13.4 million,( +43%on 2022);consolidated net profit at€ 6.2 million,quadrupled compared to 2022 ( € 1.2 million). " The FY2023 results confirmfurther progress of theGroup , which continues to expand, as evidenced by the 7.6% average annual growth we...

TVM Capital Healthcare Announces US$ 17 Million Investment into neurocare

neurocare, through its digital therapy platform (DTP), provides a holistic and patient centric treatment for a variety of psychological or neurological conditions. It uses innovative mental health care methods and tools including sleep assessment, therapeutics, psychotherapy, TMS and neurofeedback, all supervised within a cloud-based solution, to empower clinicians and deliver individualized care. Following a detailed assessment of the patient's condition, neurocare supports clinicians in…

Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05…

The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid arthritisAlvotech is the first company to publicly announce positive topline results from a patient study evaluating a biosimilar candidate to Simponi or Simponi Aria Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...

Bioforum the Data Masters Introduces SUBMIT24: A Free of Charge and…

SUBMIT24 is proud to align with the Clinical Data Interchange Standards Consortium (CDISC), a global nonprofit organization that develops and maintains standards for clinical research. Built on the CDISC standards, SUBMIT24 is designed to streamline the data validation process and enhance efficiency in clinical research. With its user-friendly interface and advanced features, SUBMIT24 empowers users to validate clinical data with ease and accuracy. SUBMIT24 is proud to align with the Clinical...

Calliditas Announces Positive NefIgArd Open Label Extension Results

The OLE study was designed to provide 9 months of treatment with Nefecon for all patients who completed the NefIgArd study and who at that time had > 1g/g of proteinuria over 24h and > 30 ml/min of eGFR. All enrolled OLE patients continued on optimized RAS inhibitor therapy (ACEs and/or ARBs) and were treated for 9 months with Nefecon 16mg per day, with a follow-up visit three months after completion of treatment. Primary assessment was based on UPCR and eGFR at 9 months. A total of 119…

Tetra Pharm Technologies and Glysious Announce Collaboration to Develop…

Tetra Pharm Technologies has focused intensively on formulation expertise, that is, how the molecules are effectively integrated with a drug delivery system to reach their desired targets. Glysious has worked rigorously on the development of an adhesive patch for transdermal drug delivery since the company's incorporation in 2020. Tetra Pharm Technologies has focused intensively on formulation expertise, that is, how the molecules are effectively integrated with a drug delivery system to…

Precision oncology company Flindr Therapeutics announces €20 million Series A…

The Company utilizes the "ImmunoGram Drug Discovery Engine", which has evolved from seminal work in the laboratories of the Netherlands Cancer Institute (NKI) and the Oncode Institute. This approach involves reverse-translating the heterogeneity in tumor-specific and host-specific factors, as commonly seen in patients in the clinic, into lab-based biological models to screen for and select the most important drug targets involved in patient clinical response. The Company utilizes…

Altri Comunicati